A Study to Evaluate the Safety and Effectiveness of AK002 in Patients with Active Eosinophilic Gastritis
Rochester, MN; Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate the effectiveness and safety of 4 doses of AK002 in patients with moderate to severe EG and/or EGE when compared to placebo.
A Study to Evaluate the Safety, Tolerability, and Activity of Escalating Doses of AK002 in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
The purpose of this study is to evaluate the safety, tolerability, and activity of escalating doses of AK002 in patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE).
A Study of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and/or duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long after the acute infection is over. The exact reason why certain individuals develop these symptoms whereas others don't is not exactly clear. The researchers are studying changes in gastrointestinal permeability (movement of contents across the lining of the intestine) and transit (movement of food through the gastrointestinal tract). The researchers are also studying if there are any genetic risk factors that are associated with development of this disorder.
Mucosal and Microbiota Changes During Acute Campylobacteriosis
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.